Supporting these data, Daenthanasanmak et al. (2019) demonstrated that SIRT1 deletion in T cells leads to an increase in p53 acetylation, promoting Treg stability, thus making sirtuins a potential target for the treatment of certain autoimmune diseases and allograft survival [90]. The gene discussed is SIRT1; the disease is autoimmune disease.